OBJECTIVE: The purpose of this study was to determine the vaginal retention of five nonoxynol-9 intravaginal contraceptives. METHOD: An open-label crossover study in 10 premenopausal volunteers was performed at an outpatient clinical research center. The outcomes are described utilizing the median and range. RESULT: At 8 h post-instillation, the median amounts of nonoxynol-9 present in the vagina were: Delfon 7.68 mg, Conceptrol 5.18 mg, Advantage 24 1.95 mg, VCF 1.74 mg, and Semicid 1.51 mg respectively. Our calculated theoretical minimal amount needed to protect against HIV infection is 2.00 mg. CONCLUSION: The best vehicle for retaining nonoxynol-9 in the vagina appears to be foam. Further research in the effectiveness of nonoxynol-9 in prevention of the spread of HIV infection should be directed toward the use of foam vehicles to deliver nonoxynol-9 to the vagina.
RCT Entities:
OBJECTIVE: The purpose of this study was to determine the vaginal retention of five nonoxynol-9 intravaginal contraceptives. METHOD: An open-label crossover study in 10 premenopausal volunteers was performed at an outpatient clinical research center. The outcomes are described utilizing the median and range. RESULT: At 8 h post-instillation, the median amounts of nonoxynol-9 present in the vagina were: Delfon 7.68 mg, Conceptrol 5.18 mg, Advantage 24 1.95 mg, VCF 1.74 mg, and Semicid 1.51 mg respectively. Our calculated theoretical minimal amount needed to protect against HIV infection is 2.00 mg. CONCLUSION: The best vehicle for retaining nonoxynol-9 in the vagina appears to be foam. Further research in the effectiveness of nonoxynol-9 in prevention of the spread of HIV infection should be directed toward the use of foam vehicles to deliver nonoxynol-9 to the vagina.
Authors: Ronald S Veazey; Thomas J Ketas; Jason Dufour; Terri Moroney-Rasmussen; Linda C Green; P J Klasse; John P Moore Journal: J Infect Dis Date: 2010-09-01 Impact factor: 5.226
Authors: Claire J Forbes; Deborah Lowry; Leslie Geer; Ronald S Veazey; Robin J Shattock; Per Johan Klasse; Mark Mitchnick; Laurie Goldman; Lara A Doyle; Brendan C O Muldoon; A David Woolfson; John P Moore; R Karl Malcolm Journal: J Control Release Date: 2011-08-12 Impact factor: 9.776
Authors: F C Krebs; S R Miller; B J Catalone; P A Welsh; D Malamud; M K Howett; B Wigdahl Journal: Antimicrob Agents Chemother Date: 2000-07 Impact factor: 5.191
Authors: Claire J Forbes; Clare F McCoy; Diarmaid J Murphy; A David Woolfson; John P Moore; Abbey Evans; Robin J Shattock; R Karl Malcolm Journal: J Pharm Sci Date: 2014-03-01 Impact factor: 3.534
Authors: Bradley J Catalone; Tina M Kish-Catalone; Lynn R Budgeon; Elizabeth B Neely; Maelee Ferguson; Fred C Krebs; Mary K Howett; Mohamed Labib; Robert Rando; Brian Wigdahl Journal: Antimicrob Agents Chemother Date: 2004-05 Impact factor: 5.191